Get the Stockscreener App
7.96
0.13%
0.010
Atara Biotherapeutics Inc stock is traded at $7.96, with a volume of 22,267.
It is up +0.13% in the last 24 hours and up +6.28% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$7.95
Open:
$7.94
24h Volume:
22,267
Relative Volume:
0.39
Market Cap:
$54.37M
Revenue:
$100.44M
Net Income/Loss:
$-133.16M
P/E Ratio:
-0.309
EPS:
-25.76
Net Cash Flow:
$-94.85M
1W Performance:
+0.25%
1M Performance:
+6.28%
6M Performance:
-34.49%
1Y Performance:
-3.63%
1-Day Range:
$7.80
$8.145
1-Week Range:
$7.6825
$8.25
52-Week Range:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
7.96 | 54.37M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Atara Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Long Term Trading Analysis for (ATRA) - news.stocktradersdaily.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Northern Trust Corp Purchases New Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Short Interest Update - Defense World
Bank of America Corp DE Acquires 1,543 Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
Redmile Group, LLC's Strategic Acquisition in Atara Biotherapeutics Inc - GuruFocus
Here's Why You Should Consider Buying Atara Biotherapeutics Stock - Barchart.com
Biotech Pioneer Pascal Touchon Joins CDR-Life Board: Former Atara CEO to Drive T Cell Platform Innovation - Stock Titan
(ATRA) Trading Advice - news.stocktradersdaily.com
Atara Biotherapeutics (NASDAQ:ATRA) & Turnstone Biologics (NASDAQ:TSBX) Financial Analysis - Defense World
Top Executives at Atara Biotherapeutics Make Significant Stock Sales! - TipRanks
Atara Biotherapeutics Executives Sell Shares for Tax Obligations - TradingView
Citadel Advisors LLC Has $3.56 Million Position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - BioSpace
Atara Biotherapeutics (ATRA) Expands Board Following $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors | ATRA Stock News - GuruFocus
Atara Biotherapeutics Reports Strong Q1 2025 Results - TipRanks
(ATRA) Investment Analysis and Advice - news.stocktradersdaily.com
Atara Biotherapeutics Announces $16M Stock Offering - TipRanks
Atara Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Atara Biotherapeutics: Q1 Earnings Snapshot - CT Insider
Atara Biotherapeutics sets stock and warrant offering prices By Investing.com - Investing.com India
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics (ATRA) Announces $16M Share Offering - GuruFocus
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress | ATRA Stock News - GuruFocus
Atara Biotherapeutics sets stock and warrant offering prices - Investing.com
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - BioSpace
Atara Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering - GuruFocus
Atara Biotherapeutics, Inc. SEC 10-Q Report - TradingView
Atara Biotherapeutics Announces Pricing of $16 Million Offering | ATRA Stock News - GuruFocus
Atara Biotherapeutics Announces Major Workforce Reduction - TipRanks
Atara Biotherapeutics To Reduce Workforce By 30% - marketscreener.com
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | President and CEO |
May 16 '25 |
Sale |
6.76 |
3,276 |
22,156 |
70,847 |
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):